The Hybrid Vaccine Trial Design That Could Render Pure RCTs Obsolete
A landmark NEJM editorial argues combining RCT and observational data can unlock vaccine effectiveness insights no single design can...
The 2-Week Window: What a Phase 1 iPSC Trial Teaches Us About Designing Cell Therapy Studies That Can Actually Win Approval
A Nature Medicine phase 1 iPSC neural progenitor trial in subacute spinal cord injury shows how to build the...
The Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and...
Ambient AI Is Not Losing Your Trial Data. It’s Quietly Deciding What Counts.
Ambient AI scribes reduce physician burnout—but a Lancet case reveals they systematically drop psychosocial context that drives protocol adherence...
The 2024 McDonald Criteria’s Lancet Neurology Publication Signals a Mandatory Protocol Audit for Active MS Trials
The 2024 McDonald MS criteria raised diagnosis rates 28% and cut median time to diagnosis from 84 to 40...
The FDA’s Psychedelic Guidance Is Really a Study-Design Reckoning
The FDA's July 2026 psychedelic guidance is nonbinding on paper. In practice it tells psilocybin, LSD, and MDMA developers...
Digital Twins Are Rewriting Clinical Trial Math. The Validation Problem Could Erase the Gains.
Biotech's digital twin rush is outpacing regulatory frameworks. Without standardized qualification, sponsors risk building trial strategies on unvalidated…
The Fentanyl Vaccine Is Real. The Evidence Strategy Isn’t.
ARMR Sciences' fentanyl vaccine entered Phase 1 in January 2026 with 40 participants. The science is credible. The path...
The Two-Fisted Antibody: What the 10E8.4/iMab Phase 1 Trial Teaches Us About Designing for Complexity
A Nature Medicine phase 1 trial of bispecific HIV antibody 10E8.4/iMab shows how partially randomized adaptive design handles dual-mechanism...
The PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.
The PARTNERS trial opened BVD enrollment July 2, 2026, testing MBP134 and obeldesivir for a hemorrhagic fever that kills...